These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29912062)

  • 1. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.
    Peters L; Laut K; Resnati C; Del Campo S; Leen C; Falconer K; Trofimova T; Paduta D; Gatell J; Rauch A; Lacombe K; Domingo P; Chkhartishvili N; Zangerle R; Matulionyte R; Mitsura V; Benfield T; Zilmer K; Khromova I; Lundgren J; Rockstroh J; Mocroft A;
    AIDS; 2018 Sep; 32(14):1995-2004. PubMed ID: 29912062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study.
    Nikolaichuk M; Mocroft A; Wandeler G; Szlavik J; Gottfredsson M; Reikvam DH; Svedhem V; Elinav H; Laguno M; Mansinho K; Devitt E; Chkhartishvili N; Behrens G; Bogner J; Viard JP; Winston A; Benfield T; Leen C; Fursa O; Rockstroh J; Peters L;
    HIV Med; 2023 Feb; 24(2):224-230. PubMed ID: 35934954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
    Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
    Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
    Boerekamps A; Newsum AM; Smit C; Arends JE; Richter C; Reiss P; Rijnders BJA; Brinkman K; van der Valk M;
    Clin Infect Dis; 2018 Apr; 66(9):1352-1359. PubMed ID: 29186365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences.
    Fursa O; Mocroft A; Lazarus JV; Amele S; Lundgren J; Matulionyte R; Rasmussen LD; Rockstroh JK; Parczewski M; Jilich D; Moreno S; Vassilenko A; Lacombe K; Wandeler G; Borodulina E; Brännström J; Wiese L; Orkin C; Behrens GMN; Mansinho K; Portu JJ; Peters L;
    AIDS; 2022 Mar; 36(3):423-435. PubMed ID: 34690281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
    Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
    AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
    Grint D; Peters L; Schwarze-Zander C; Beniowski M; Pradier C; Battegay M; Jevtovic D; Soriano V; Lundgren JD; Rockstroh JK; Kirk O; Mocroft A;
    HIV Med; 2013 Nov; 14(10):614-23. PubMed ID: 23869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients.
    Macías J; Téllez F; Rivero-Juárez A; Palacios R; Morano LE; Merino D; Collado A; García-Fraile L; Omar M; Pineda JA;
    J Viral Hepat; 2019 Jan; 26(1):48-54. PubMed ID: 30199593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
    Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
    HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
    Cope R; Glowa T; Faulds S; McMahon D; Prasad R
    AIDS Patient Care STDS; 2016 Feb; 30(2):51-5. PubMed ID: 26744994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.
    Uriarte-Pinto M; Navarro-Aznarez H; De La Llama-Celis N; Arazo-Garcés P; Martínez-Sapiña AM; Abad-Sazatornil MR
    Int J Clin Pharm; 2018 Jun; 40(3):608-616. PubMed ID: 29556931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.